41490-13-5

Basic information

• Product Name: 3,5-Dichloro-4-phenylmethoxybenzoic acid
• Synonyms: 3,5-Dichloro-4-phenylmethoxybenzoic acid;4-Benzyloxy-3,5-dichloro-benzoic acid
• CAS NO: 41490-13-5
• Molecular Formula: C₁₄H₁₀Cl₂O₃
• Molecular Weight: 297.1334
• Mol File: 41490-13-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 438°Cat760mmHg
• Flash Point: 218.7°C
• Appearance: /
• Density: 1.411g/cm³
• Vapor Pressure: 1.91E-08mmHg at 25°C
• Refractive Index: 1.621
• CAS DataBase Reference: 3,5-Dichloro-4-phenylmethoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dichloro-4-phenylmethoxybenzoic acid(41490-13-5)
• EPA Substance Registry System: 3,5-Dichloro-4-phenylmethoxybenzoic acid(41490-13-5)

Safety Data

• Hazardous Substances Data: 41490-13-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H10Cl2O3/c15-11-6-10(14(17)18)7-12(16)13(11)19-8-9-4-2-1-3-5-9/h1-7H,8H2,(H,17,18)

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 3337-59-5 methyl 3,5-dichloro-4-hydroxybenzoate 
• 100-39-0 benzyl bromide 
• 536974-83-1 4-benzyloxy-3,5-dichlorobenzoic acid methyl ester 
• 40689-39-2 ethyl 3,5-dichloro-4-(benzyloxy)benzoate 
• 3336-41-2 3,5-dichloro-4-hydroxybenzoic acid 

Downstream Products

• 354575-15-8 3,5-dichloro-4-benzoxybenzoic chloride 
• 1272528-06-9 methyl 4-(4-(benzyloxy)-3,5-dichlorobenzamido)benzoate 
• 848297-61-0 methyl 4-(3,5-dichloro-4-hydroxybenzamido)benzoate 
• 1272528-30-9 methyl 4-(4-(tert-butoxy)-3,5-dichlorobenzamido)benzoate 
• 1309825-71-5 4-(4-(tert-butoxy)-3,5-dichlorobenzamido)benzoic acid 
• 888731-81-5 (4-benzyloxy-3,5-dichlorophenyl)-(5-nitro-2,3-dihydroindol-1-yl)-methanone 

Relevant articles and documents

AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS

The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agents and medicaments comprising such compounds. The compounds are based on a general structure A-L-B, wherein A is a group of formula (II) or of formula (III): or of formula (IV) or of formula (V) B is a group of formula (III), (IV), or (V), or a group of formula (VI) or a group of formula –R10Z, wherein: Z is selected from -CO2R', -CONR'R'', -SO2R' wherein R' and R'' are independently H or C1-C4 alkyl; and R10 is a C1-C4 alkylene or alkenylene group; and L represents a linker group which is a saturated or unsaturated chain of 5 to 13 carbon atoms.

Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist

A ligand-based virtual screening exercise examining likely bioactive conformations of AM 580 (2) and AGN 193836 (3) was used to identify the novel, less lipophilic RARα agonist 4-(3,5-dichloro-4-ethoxybenzamido)benzoic acid 5, which has good selectivity over the RARβ and RARγ receptors. Analysis of the medicinal chemistry parameters of the 3,5-substituents of derivatives of template 5 enabled us to design a class of drug-like molecules with lower intrinsic clearance and higher oral bioavailability which led to the novel RARα agonist 4-(3-chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid 56 that has high RARα potency and excellent selectivity versus RARβ (2 orders of magnitude) and RARγ (4 orders of magnitude) at both the human and mouse RAR receptors with improved drug-like properties. This RARα specific agonist 56 has high oral bioavailability (>80%) in both mice and dogs with a good PK profile and was shown to be inactive in cytotoxicity and genotoxicity screens.

Therapeutic Aryl-Amido-Aryl Compounds and Their Use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, a